Table 2.

Clinical trials registered in Clinical Trials.gov evaluating efficacy and safety of Tranilast in a variety of diseases.

Condition or disease	Intervention/treatment	Phase	Participants	Clinical trial identifier
Mucinoses	0.1g each time, three times a day,12 months	Early Phase 1	56	NCT03490708
Scleredema Adultorum	0.1g each time, three times a day,6 months	Early Phase 1	56	NCT03512873
Sarcoidosis	0.1g each time, three times a day	Early Phase 1	56	NCT03528070
Gout Hyperuricemia	Combination Tranilast and Febuxostat	Phase 2	24	NCT00995618
Active Rheumatoid Arthritis	Tranilast, 300 mg/day Tranilast, 150 mg/day	Phase 2	250	NCT00882024
Gout Hyperuricemia	Tranilast and Allopurinol	Phase 2	24	NCT01052987
Gout Hyperuricemia	1-Tranilast 300 mg QD Allopurinol 400 mg QD. 2-Tranilast, 300 mg QD Allopurinol 600 mg QD	Phase 2	112	NCT01109121
Allergic Conjunctivitis	Olopatadine 0.1% one drop in one eye Tranilast 0.5% one drop in one eye	Phase 4	50	NCT00818805